Profile data is unavailable for this security.
About the company
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
- Revenue in USD (TTM)0.00
- Net income in USD-127.27m
- Incorporated2017
- Employees110.00
- LocationBiomea Fusion Inc900 Middlefield Road, 4Th FloorREDWOOD CITY 94063United StatesUSA
- Phone+1 (650) 980-9099
- Fax+1 (302) 655-5049
- Websitehttps://www.biomeafusion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotechnology Inc | 226.63m | 15.38m | 149.54m | 185.00 | 9.63 | 2.93 | 5.56 | 0.6599 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| Capricor Therapeutics Inc | 27.10m | -24.31m | 150.15m | 101.00 | -- | 8.09 | -- | 5.54 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 150.53m | 65.00 | -- | 1.45 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 150.87m | 74.00 | -- | 0.4914 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 152.99m | 29.00 | -- | 1.91 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Yubo International Biotech Ltd | 455.72k | -1.26m | 154.57m | 18.00 | -- | -- | -- | 339.18 | -0.0105 | -0.0105 | 0.0038 | -0.0172 | 0.2488 | 0.4126 | 5.27 | 25,317.78 | -70.32 | -- | -- | -- | 80.24 | -- | -282.61 | -- | 0.1487 | -4,023.75 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Generation Bio Co | 9.96m | -169.06m | 155.68m | 174.00 | -- | 1.18 | -- | 15.63 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 157.63m | 22.00 | -- | 3.18 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Metagenomi Inc | -100.00bn | -100.00bn | 158.47m | 237.00 | -- | 0.575 | -- | -- | -- | -- | -- | 7.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 159.23m | 110.00 | -- | 1.18 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 159.47m | 249.00 | -- | -- | -- | 0.5283 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| INmune Bio Inc | 131.00k | -34.50m | 159.64m | 11.00 | -- | 4.99 | -- | 1,218.66 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 164.75m | 36.00 | 164.89 | 54.23 | 57.93 | 3.67 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -159.13m | 165.95m | 24.00 | -- | -- | -- | -- | -11.48 | -11.48 | 0.00 | -6.10 | 0.00 | -- | -- | 0.00 | -281.52 | -214.69 | -2,060.72 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.75 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 168.77m | 84.00 | -- | -- | -- | 48.22 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
Data as of Jul 02 2024. Currency figures normalised to Biomea Fusion Inc's reporting currency: US Dollar USD
68.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.36m | 14.90% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.49m | 12.48% |
| Cormorant Asset Management LPas of 12 Jun 2024 | 3.57m | 9.93% |
| Laurion Capital Management LPas of 31 Mar 2024 | 2.72m | 7.57% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 2.11m | 5.87% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.66m | 4.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.31m | 3.64% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.27m | 3.54% |
| Driehaus Capital Management LLCas of 31 Mar 2024 | 1.19m | 3.32% |
| Aisling Capital Management LPas of 31 Mar 2024 | 798.76k | 2.22% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
